Keywords: zymogenetics, starts, combined, il-21, rituxan, study, usa-based
Zymogenetics starts combined IL-21 and Rituxan study
Article | 17 July 2006
USA-based drugmaker Zymogenetics says that it has initiated a Phase I trial of interleukin 21 in combination with Rituxan (rituximab), co-developed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
